publication date: Jul. 12, 2019

In Brief

Emory Winship Cancer Institute awarded NCI lung cancer SPORE grant

Winship Cancer Institute of Emory University has been awarded NCI’s five-year, $9.7 million Specialized Program of Research Excellence grant  to study new approaches for lung cancer treatment.

This new grant (P50CA217691) is the first to be awarded in the state of Georgia and one of four SPORE grants in the U.S. dedicated to lung cancer.

Led by Suresh S. Ramalingam and Haian Fu, the translational cancer research program will support a team of Winship investigators in the fields of immunology, pharmacology, medical oncology, radiation oncology, surgical oncology, and pathology to address major therapeutic challenges faced by patients with lung cancer.

“We will investigate how to improve immunotherapy for patients, how to test novel targeted therapies to overcome resistance, and how to accelerate new treatment paradigms,” said Ramalingam, Winship’s deputy director and contact principal investigator.  “By conducting cutting-edge clinical trials that build on a very strong biological basis, we will improve outcomes for patients with lung cancer.”

“Guided by urgent clinical needs, the multi-disciplinary team of physician and basic scientists will work together to not only address current challenges, but also to develop the next generation of innovative therapeutic strategies for cancer patients,” said Fu, a multi-principal investigator of the grant and chair of the Department of Pharmacology and Chemical Biology. He also leads Winship’s Discovery and Developmental Therapeutics Program along with Ramalingam.

In addition to Ramalingam, Fu, and Winship’s Executive Director Walter Curran, other key contributors to the NCI SPORE grant from NIH include Rafi Ahmed, Madhusmita Behera, Zhengjia Chen, Xingming Deng, Felix Fernandez, Douglas Graham, Anthea Hammond, Michael Kutner, Adam Marcus, … Continue reading Emory Winship Cancer Institute awarded NCI lung cancer SPORE grant

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.